Journal
CHEMISTRY-A EUROPEAN JOURNAL
Volume 24, Issue 63, Pages 16783-16790Publisher
WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.201803725
Keywords
anticancer drugs; bioorthogonal catalysis; combination therapy; irinotecan; palladium
Categories
Funding
- CRUK
- EPSRC [EP/N021134/1]
- EC [H2020-MSCA-IF-2014-658833]
- CMVM of the University of Edinburgh
- CRUK Ph.D. Fellowship
Ask authors/readers for more resources
SN-38, the active metabolite of irinotecan, is released upon liver hydrolysis to mediate potent antitumor activity. Systemic exposure to SN-38, however, also leads to serious side effects. To reduce systemic toxicity by controlling where and when SN-38 is generated, a new prodrug was specifically designed to be metabolically stable and undergo rapid palladium-mediated activation. Blocking the phenolic OH of SN-38 with a 2,6-bis(propargyloxy)benzyl group led to significant reduction of cytotoxic activity (up to 44-fold). Anticancer properties were swiftly restored in the presence of heterogeneous palladium (Pd) catalysts to kill colorectal cancer and glioma cells, proving the efficacy of this novel masking strategy for aromatic hydroxyls. Combination with a Pd-activated 5FU prodrug augmented the antiproliferative potency of the treatment, while displaying no activity in the absence of the Pd source, which illustrates the benefit of achieving controlled release of multiple approved therapeutics-sequentially or simultaneously-by the same bioorthogonal catalyst to increase anticancer activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available